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In Western countries, invasive infections caused by M1T1 serotype group A Streptococcus (GAS) are
epidemiologically linked to mutations in the control of virulence regulatory 2-component operon (covRS). In
indigenous communities and developing countries, severe GAS disease is associated with genetically diverse
non-M1T1 GAS serotypes. Hypervirulent M1T1 covRS mutant strains arise through selection by human
polymorphonuclear cells for increased expression of GAS virulence factors such as the DNase Sda1, which
promotes neutrophil resistance. The GAS bacteremia isolate NS88.2 (emm 98.1) is a covS mutant that
exhibits a hypervirulent phenotype and neutrophil resistance yet lacks the phage-encoded Sda1. Here, we
have employed a comprehensive systems biology (genomic, transcriptomic, and proteomic) approach to
identify NS88.2 virulence determinants that enhance neutrophil resistance in the non-M1T1 GAS genetic
background. Using this approach, we have identified streptococcal collagen-like protein A and general stress
protein 24 proteins as NS88.2 determinants that contribute to survival in whole blood and neutrophil
resistance in non-M1T1 GAS. This study has revealed new factors that contribute to GAS pathogenicity that
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In Western countries, invasive infections caused by M1T1 serotype group A Streptococcus (GAS) are 
epidemiologically linked to mutations in the control of virulence regulatory two-component operon (covRS). 
In indigenous communities and developing countries, severe GAS disease is associated with genetically 
diverse non-M1T1 GAS serotypes. Hypervirulent M1T1 covRS mutant strains arise through selection by 
human polymorphonuclear cells for increased expression of GAS virulence factors such as the DNase Sda1, 
which promotes neutrophil resistance. The GAS bacteraemia isolate NS88.2 (emm 98.1), is a covS mutant 
that exhibits a hypervirulent phenotype and neutrophil resistance, yet lacks the phage-encoded Sda1. Here, 
we have employed a comprehensive systems biology (genomic, transcriptomic and proteomic) approach to 
identify NS88.2 virulence determinants that enhance neutrophil resistance in the non-M1T1 GAS genetic 
background. Using this approach, we have identified streptococcal collagen-like protein A and general 
stress protein 24 proteins as NS88.2 determinants that contribute to survival in whole blood and neutrophil 
resistance in non-M1T1 GAS. This study has revealed new factors that contribute to GAS pathogenicity that 
may play important roles in resisting innate immune defences and the development of human invasive 
infections.  




Streptococcus pyogenes (group A Streptococcus, GAS) infection is responsible for human mortality and 
morbidity on a global scale. Severe disease pathologies caused by GAS include acute suppurative invasive 
conditions such as bacteraemia, streptococcal toxic shock-like syndrome (STSS), and necrotising fasciitis, 
as well as post-infectious immune-mediated sequelae in the form of acute rheumatic fever and 
glomerulonephritis (1). Epidemiologically, severe GAS infections in developed countries are dominated by 
a handful of serotypes (2). Notably, the well-characterised M1T1 GAS clone is frequently isolated from 
invasive infection (3). A resurgence in the rates of severe GAS disease over the last three decades has been 
paralleled by the global emergence of clonal hypervirulent M1T1 and M3 isolates (4, 5). In contrast, diverse 
GAS serotypes are endemic in indigenous and developing communities, where no serotype predominates 
(6). Necrotising fasciitis isolates from tropical northern Australia exhibit emm diversity, and serotypes that 
monopolise disease epidemiology in the Western hemisphere are seldom encountered (7). Thus isolates 
from indigenous and developing areas make ideal model organisms for the study of emergent, invasive GAS 
strains.  
Multiple factors appear to underlie the pandemic spread of M1T1, including the recent acquisition of phage-
encoded virulence factors that dampen innate immune responses (8, 9). Bacteriophage-encoded 
deoxyribonuclease Sda1 enables M1T1 GAS to degrade neutrophil extracellular traps (NETs) (10), and the 
transfer of Sda1 to M1T1 provides a selective trigger for acquiring mutations in the control of virulence 
covRS regulator (11). Certain mutations of covRS result in the up-regulation of many GAS virulence factor 
genes including sda1 and those encoding streptolysin O and hyaluronic acid capsule (12-14). Furthermore, 
expression of the broad spectrum cysteine protease SpeB is also abrogated as a result of covRS mutation, 
preserving the integrity of many GAS virulence proteins (15) and allowing the pathogen to acquire cell-
surface plasmin activity capable of degrading fibrin clots which impede bacterial dissemination (16). Thus, 
the in vivo selection for GAS covRS mutants by the host innate immune system inadvertently initiates a 
permanent genetic switch to a hypervirulent phenotype, capable of resisting neutrophil-mediated killing and 
subverting the host plasminogen activation system for systemic infection (1). 
The mechanisms coordinating the virulence of non-M1T1 GAS are less defined. It has recently been shown 
that mutation of covRS in a range of GAS M-types results in a genetic switch analogous to that seen in 
M1T1 (17), and that GAS of divergent M-types with mutations in covRS and/or the regulatory ropB gene 
are frequently isolated from STSS patients (18). However, the mechanisms underlying the hypervirulent 
phenotype in the absence of the bacteriophage encoded DNase Sda1 are yet to be characterised. The clinical 
isolate NS88.2 (emm 98.1) encodes a mutated covS gene, is highly-encapsulated, acquires cell-surface 
plasmin activity, is resistant to killing by human neutrophils and is hypervirulent in a humanised 
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plasminogen mouse model (17, 19), whilst repair of the covS  mutation renders NS88.2 highly sensitive to 
neutrophil killing (17).  Here, we apply a comprehensive systems biology approach to analyse this 
representative non-M1 isolate, in order to identify virulence determinants contributing to GAS neutrophil 
resistance, leading to invasive infection in the absence of sda1. 
MATERIALS AND METHODS 
Ethics statement  
Permission to collect human blood under informed consent was approved by the UCSD Human Research 
Protections Program and the University of Wollongong Human Ethics Committee. All animal use and 
procedures were approved by the UCSD Institutional Animal Care and Use Committee and the University 
of Wollongong Animal Ethics Committee.  
Bacterial strains and growth conditions  
The widely disseminated GAS isolate 5448 (M1T1) and the animal-passaged covS mutant derivative 
5448AP have been previously characterised (11). Clinical GAS isolate NS88.2 (emm 98.1) was obtained 
from a patient with severe bacteraemia in Australia’s Northern Territory and contains a covS mutation (20). 
Isogenic NS88.2 derivative strains with the covS mutation repaired (NS88.2rep) and the covS regulator 
returned to non-functionality via reverse complementation (NS88.2covS) have been previously described 
(17). GAS isolates were routinely cultured at 37°C on horse blood agar (HBA), Todd-Hewitt agar (THYA) 
or in static cultures of yeast-supplemented (1% [w/v]) Todd-Hewitt broth (THBY). GAS strains containing 
the pDCerm derivative constructs (pDC-gls24 or pDC-sclA) were cultured in the presence of 2 µg.ml-1 
erythromycin. GAS cultures for use in microarray experiments were cultured in THBY supplemented with 
1.5% (w/v) yeast extract. GAS cultures for biofilm, keratinocyte assays and in vivo adherence were grown 
in Todd-Hewitt broth (THB) without yeast supplementation. 
Biofilm formation  
Measurement of biofilm formation on polystyrene essentially as previously described (21). Briefly, 12 
individual wells of a tissue culture treated 96-well microtitre plate were inoculated with 150 µl of overnight 
culture diluted 1:100 in THB and incubated for 24 h at 37°C. Plates were washed with sterile phosphate-
buffered saline (PBS), and cells were fixed with 4% paraformaldehyde. Wells were stained with 0.2% 




Epithelial cell adherence and invasion assay  
Assays measuring the adherence of GAS to human keratinocyte cells (HaCaT) were performed as 
previously described (21). Mid-logarithmic phase GAS (2 x 106 CFU) were added to HaCaT cells (2 x 105 
cells) in the wells of a 24 well plate, centrifuged for 10 min at 500 x g and incubated at 37°C in 5% CO2. 
For adherence assays, plates were incubated for 30 min prior to washing with PBS with subsequent release 
and lysing of cells. Bacteria were serially diluted and plated on THYA for enumeration. For invasion assays, 
plates were incubated for 2 h. Plates were then washed as previously described and treated with gentamicin 
and penicillin G. Plates were then incubated for a further 2 h, prior to washing and treating as described 
above. Bacterial adherence and invasion was calculated as a percentage of the original inoculum. Statistical 
significance was determined using one-way ANOVA with the Tukey post-hoc test. 
Murine skin adherence assay  
Adherence of GAS to mice flank was assessed in vivo as previously conducted (21). Mid-logarithmic phase 
phase GAS culture (2 x 105 CFU) was spotted onto THYA plates, air-dried and agar disks containing the 
bacteria excised using a biopsy punch. Bacterial agar disks were affixed to a total of 10 CD1 mice, each 
with 3 disks (one each of the wild type NS88.2, NS88.2rep and NS88.2covS). After 1 h, the mice were 
euthanised and skin under the bacterial disks was excised. Tissue was thoroughly washed with sterile PBS 
to remove non-adherent bacteria prior to homogenisation. Homogenate was serially diluted in sterile PBS 
and plated on THYA for enumeration. Bacterial adherence was calculated as a percentage of the original 
inoculum. Statistical significance was determined using one-way ANOVA with the Tukey post-hoc test. 
Construction of NS88.2 isogenic deletion mutants and complemented strains 
The sclA and gls24 genes were isogenically removed from the NS88.2 genome via precise, allelic 
replacement essentially as described previously (22). Briefly, 250 bp upstream and downstream regions of 
sclA and gls24 and the chloramphenicol acetyltransferase (cat) gene were amplified via PCR using sclA 
upstream sense (5’-TTCTTCCTGTCTGTTTACATTTCAAAAAAGAGTGACC-3’) and antisense (5’- 
GTGGCTTTTTTCTCCATATGTTGTTCTCTCTTTCTCT-3’) primers; sclA downstream sense (5’- 
GTGGCTGGGCGGGGCGTAATCCTCTAAATTGAGAGGCCT-3’) and antisense (5’- 
TTGTCCTCTTCTGTTTTCGTTCCTCATCTAGCATTT-3’) primers; gls24 upstream sense (5’- 
TTCTTCCTGTCTGTTTAAGGTATTATTGATCAATTTC-3’) and antisense (5’- 
GTGGCTTTTTTCTCCATGTTCACGCCATCACGTACAG-3’) primers; gls24 downstream sense (5’- 
GTGGCTGGGCGGGGCGTAATCATATGTCGTCAATTAGGT-3’) and antisense (5’- 
TTGTCCTCTTCTGTTTATGTCCCCTTTATTTATCTT-3’) primers; cat sense (5’- 
GGAGAAAAAAGCCACTGGATATACCACC-3’) and antisense (5’- 
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ACGCCCCGCCCAGCCACTCATCGCAATACTGTT-3’) primers. PCR amplicons were subsequently 
combined with PmeI digested pHY304-LIC and recombinant vectors constructed using ligation independent 
cloning. Vectors were introduced into NS88.2 via electroporation and double cross-over mutants encoding 
in-frame allelic exchanges of sclA or gls24 with cat generated via growth of transformants at 30°C prior to 
shifting to the non-permissive temperature for plasmid replication (37°C). The absence of erythromycin, 
gene target and presence of cat was confirmed by PCR of each mutant strain. Complementation of the 
NS88.2ΔsclA and NS88.2Δgls24 isogenic deletion mutants was conducted via cloning of the sclA and gls24 
protein coding sequences into the Gram-positive constitutive expression vector pDCerm (23). Primers 
annealing to sclA (sense primer 5’-
CCGGTCTAGATAAAGGAGGACTCTTCATGTTGACATCAAAACACCACAA-3’, antisense primer 5’- 
ATATGAATTCTTAGTTGTTTTCTTTGCGTTTTGT-3’) and gls24 (sense primer 5’- 
CCGGTCTAGATAAAGGAGGACTCTTCGTGGAAGTTGGAAAAAAACAAGTTGCCG-3’, antisense 
primer 5’-ATATGAATTCTTATTTTACACGTGGCTCAGCTTTTTGATC-3’) were designed with 5’ 
extensions containing XbaI and EcoRI restriction sites and amplified via PCR. Purified gls24 and sclA 
amplicons were sub-cloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA) prior to directional cloning into 
pDCerm, generating pDC-gls24 and pDC-sclA. Recombinant plasmids (pDC-gls24 and pDC-sclA) were 
transformed into electro-competent NS88.2ΔsclA and NS88.2Δgls24 via electroporation with the presence 
of erythromycin and re-introduction of gls24 or sclA for NS88.2Δgls24 (pDC-gls24) and NS88.2ΔsclA 
(pDC-sclA) respectively confirmed via PCR screening. 
Genome sequencing, de novo assembly and annotation  
We extracted RNA-free genomic DNA from an NS88.2 liquid culture as previously described (17). 
Genomic DNA extract was read using an Illumina GAII (Illumina, San Diego, CA, USA) sequencer at the 
Australian Genome Research Facility. Raw 75mer sequence reads were assembled de novo into 298 
contigs with an average coverage of >25 using Velvet 1.0.13 (24), with iterative refinement of assembly 
parameters to obtain optimal assembly outcomes. Genomic distances between the NS88.2 scaffold and 
publicly available GAS genomes were given based upon DNA maximal unique match indexes (MUMi) 
calculated using MUMmer3 (25). Contigs in the scaffold were then reordered according to the closest 
MUMi neighbour (MGAS315, accession number: NC_004070) using the Mauve Contig Mover (26). 
Concatenated contigs were submitted to the RAST server (http://rast.nmpdr.org) (27) where ORFs were 
called using Glimmer3 (28) and putative protein function assigned from FIGfam subsystem families . 
Secreted proteins were predicted using SignalP 3.0 (29). Cell-wall associated proteins were predicted using 
the hmmer3 package (http://hmmer.org). BLAST searches and image generation were carried out using 
BLAST Ring Image Generator (BRIG) (30). Manual curation and analysis of the genome draft was 
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conducted using Artemis 12.0 (31) and read coverage mapped using BAMview (32). These sequence data 
have been submitted to the EMBL under accession number CAHN1000000 (Project: PRJEA84331).     
Two-dimensional gel electrophoresis  
Two-dimensional gel electrophoresis and peptide mass fingerprinting was conducted as previously 
described (15). Early-stationary phase GAS cultures were grown in THBY containing 28 µM of the cysteine 
protease inhibitor N-[N-(L-3-trans-carboxyirane-2-carbonyl)-L-Leucyl]-agmatine (E64) (Sigma, St Louis, 
MO, USA). GAS supernatant proteins were precipitated using TCA and equal quantities of protein loaded 
onto ReadyStrip IPG strips (Bio-Rad, Hercules, CA, USA) prior to rehydration for ≥ 15 h. Rehydrated IPG 
strips were isoelectrically focussed using a PROTEAN IEF Cell (Bio-Rad, Hercules, CA, USA). Second 
dimension separation of IPG strips was conducted using a PROTEAN Dodeca Cell (Bio-Rad, Hercules, CA, 
USA) with visualisation of protein spots using Coomassie stain. Protein spots of interest were excised, 
tryptically digested prior to release of the digested peptides into 50 mM NH4HCO3 at 37°C. Digested 
peptides were loaded onto target plates and mass spectra were generated using an AXIMA Confidence™ 
MALDI-TOF MS (Shimadzu, Kyoto, Japan). Spectra were analysed using Shimadzu Biotech Launchpad 
2.8.3 (Shimadzu, Kyoto, Japan). Peptide mass fingerprinting was conducted using exported protein coding 
sequence data from the NS88.2 genome draft and interrogated using the Mascot search algorithm available 
through the Australian Computational Proteomics Facility (http://www.apcf.edu.au). 
Transcriptional Microarray  
The oligonucleotide microarray used in this study and the method for in vitro transcriptional microarray has 
been described previously (17). Mid-logarithmic phase GAS cultures were grown in THBY and RNA 
extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA was DNase-treated and converted to 
dendrimer-labeled cDNA using the Genisphere 3DNA Array 900MPX Kit according the manufacturer’s 
guidelines. Dendrimer-labeled cDNA was hybridised to the array and labelled with Alexa Fluor 546 or 
Alexa Fluor 647. Sliders were scanned with a GenePix 4000B scanner (Molecular Devices, Sunnyvale, CA, 
USA) and images processed using GenePixPro 4.0 software (Molecular Devices, Sunnyvale, CA, USA). 
Transcriptional analyses were performed with GeneSpring GX 10 (Agilent, Santa Clara, CA, USA). All 
transcriptional microarray data were submitted to the NCBI Gene Expression Omnibus (GEO) according to 
the MIAME standards (GEO accession No. GSE23825). 
Quantitative real-time PCR  
RNA isolation from mid-logarithmic phase GAS cultured in THBY was conducted as previously described 
for microarray experiments. RNA from mid-logarithmic phase GAS cultured in whole blood was isolated 
following mid-logarithmic growth of GAS in THBY, washed once in sterile PBS and 0.2 ml of GAS 
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resuspension added to 1.8 ml of anticoagulated blood. GAS blood cultures were incubated at 37°C for 1 h 
with gentle agitation prior to hypotonic lysis of blood cultures using 40 ml of sterile dH2O and GAS 
recovery via centrifugation (7000 x g, 5 min). RNA was extracted from blood cultured GAS as previously. 
Purified GAS RNA was double DNase digested using an RNase-free DNase set (Qiagen, Hilden, Germany) 
prior to cDNA synthesis using a Tetro cDNA Synthesis kit (Bioline, London, UK). NS88.2 transcripts were 
quantified using a SensiFAST SYBR No-Rox kit (Bioline, London, UK). The absence of contaminating 
chromosomal DNA in RNA samples was confirmed via PCR analysis of purified RNA samples. Fold 
changes in expression were normalised according to amplification efficiency for each gene as described 
(33), and to the house-keeping gene proS, the expression of which does not vary with covS mutation or 
growth cycle (34).   
Whole blood growth kinetics  
Estimation of GAS ability to survive and replicate in whole blood was conducted via the Lancefield method 
as described previously (35). Venous blood from healthy donors was collected and inoculated with a one-
tenth volume of mid-logarithmic phase GAS culture and incubated at 37°C for 3 h with gentle agitation on a 
rotating mixer. Fold growth was calculated as resultant CFU/ml after 3 h over initial CFU/ml. All individual 
assays were conducted in triplicate, with a minimum of 3 donors for calculation of growth kinetics for each 
strain assayed, Statistical significance was determined using one-way ANOVA with the Tukey post-hoc 
test. 
PMN bactericidal activity assay  
Measurement of GAS resistance to PMN-mediated killing in vitro was conducted essentially as previously 
(36). Human neutrophils were purified from venous blood using a PolyMorphPrep kit (Axis-Shield, Oslo, 
Norway) as per the manufacturer’s instructions. Mid-logarithmic phase GAS (2 x 106 CFU) were added to 2 
x 105 neutrophils seeded into 96-well plates in RPMI supplemented with 2% heat-inactivated plasma and 
brought into close proximity via centrifugation (200 x g, 10 min, 4°C) prior to incubation for 30 min at 
37°C. Post-incubation, PMNs were hypotonically lysed and surviving GAS enumerated via serial dilution 
and overnight incubation on THYA. Growth controls consisted of GAS grown under identical conditions in 
the absence of PMNS. GAS survival was calculated as a percentage of GAS surviving following PMN 
incubation compared with growth controls. All individual assays were conducted in triplicate, with three 
independent assays using different blood donors. Statistical significance was determined using one-way 
ANOVA with the Tukey post-hoc test. 
NET Degradation  
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Visualisation of NET degradation was conducted as previously (10). Human neutrophils were purified from 
venous blood using a PolyMorphPrep kit (Axis-Shield, Oslo, Norway) as per the manufacturer’s 
instructions and seeded at 2 x 105 cells per well in 96-well plates. GAS were added to the wells at a 
multiplicity of infection of 1:100 (GAS:neutrophils) and Sytox Orange (Invitrogen, Carlsbad, CA, USA) 
added at a final concentration of 0.1 µM. Cells were visualised without fixation or washing using a Zeiss 
Axiovert 100 inverted microscope with appropriate fluorescent filters, and images captured with a CCD 
camera. For quantification, NETs were enumerated for each treatment by counting one transect after 
staining from 3 independent wells; a NET was defined as a discrete area of bright orange fluorescence larger 
than the size of a neutrophil. Statistical significance was determined using one-way ANOVA with the 
Tukey post-hoc test. 
Hyaluronic acid capsule determination 
Measurement of hyaluronic capsule production by the NS88.2 strains was conducted as previously 
described in (37). Chloroform extractions of capsule from mid-logarithmic phase GAS cultures were 
quantified using Stains-all (Sigma, St Louis, MO, USA). Biosynthesis of hyaluronic acid was calculated per 
CFU of GAS from the original culture, determined via serial dilution and enumeration of viable CFU. 
SpeB degradation of purified Gls24 protein 
Recombinant Gls24 protein was expressed with an incorporated N-terminal Histidine hexamer and isolated 
using Nickel affinity chromatography. The coding sequence of gls24 from NS88.2 was amplified via PCR 
using primers with 5’ extensions containing SmaI and PaeI restriction sites (sense primer 5’- 
CGCGCATGCCTGGTTCCGCGTGGCTCTGTGGAAGTTGGAAAAAAACAAGTTGCCGTTGATCTT
G-3’, antisense primer 5’-GGCCCCGGGTTATTTTACACGTGGCTCAGCTTTTTGATC-3’) and 
subcloned into pCRScript (Agilent, Santa Clara, CA, USA) prior to directional cloning into pQE30. 
Recombinant Gls24 was expressed in Escherichia coli and purified via binding to Ni-NTA resin. SpeB 
protease activity was assayed as described in (16). Purified mature SpeB protease (5 µg, Toxin 
Technologies, Sydney, Australia) was mixed with 5 µg of purified Gls24 or 25 µg of Casein (Sigma, St 
Louis, MO, USA), adjusted to a final volume of 25 µl with PBS and incubated at 37°C for 3 h. Proteolysis 
of casein and Gls24 was determined by SDS-PAGE analysis. Negative control assays containing casein, 
Gls24 or SpeB only were also included. 
RESULTS 
Reduction of NS88.2 colonisation potential due to covS mutation 
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Similar to the globally disseminated M1T1 GAS, mutation of covS in non-M1T1 GAS results in a 
hypervirulent, neutrophil resistant phenotype (17). Such mutations in the M1T1 background have come with 
a potential fitness cost, as the covS mutant displays reduced capacity for biofilm formation and epithelial 
adherence and invasion (21). To determine whether this phenomenon occurred in the non-M1T1 
background, clinical covS mutant GAS isolate NS88.2 (emm 98.1) from a case of severe bacteraemia in 
Australia’s Northern Territory (20) was compared to isogenic derivative strains with the covS mutation 
repaired (NS88.2rep) and the covS regulator returned to non-functionality via reverse complementation 
(NS88.2covS) (17). Restoration of functional covS in NS88.2rep resulted in a significant increase in biofilm 
formation compared to the wild-type NS88.2 or the reverse complemented mutant NS88.2covS, which each 
express truncated CovS (P < 0.001) (Fig. 1A). A similar result was observed with respect to the ability of 
the NS88.2 strains to adhere to and invade epithelial cells. The intact covS NS88.2rep strain showed a 
significant increase in adherence to and invasion of the HaCaT keratinocyte cell line over the covS mutant 
NS88.2 and NS88.2covS strains (P < 0.001) (Fig. 1B). This in vitro data was further corroborated by in vivo 
assays, as adhesion to live mouse skin was also compromised by covS mutation in NS88.2 and NS88.2covS 
(P < 0.01) (Fig. 1C).  
NS88.2 neutrophil resistance does not require neutrophil extracellular trap degradation 
NS88.2 is highly resistant to neutrophil killing (17); however PCR screening indicates that NS88.2 does not 
contain the sda1 gene (data not shown). The ability of NS88.2 and the isogenic covS derivative mutants 
NS88.2rep and complemented mutant NS88.2covS to degrade NETs was examined. We observed no 
significant differences in NET degradation between NS88.2, the NS88.2 derivative strains or 5448Δsda1, an 
M1T1 GAS strain with sda1 deleted via precise allelic exchange (Fig. 2). In contrast, the covRS mutant 
animal-passaged 5448AP strain exhibited significantly higher NET degradation in comparison to all of the 
NS88.2 strains and 5448Δsda1 (P < 0.001). We conclude that in the absence of Sda1, other virulence factors 
play a role in NS88.2 neutrophil resistance. To test this hypothesis, we undertook a systems biology 
approach to identify virulence determinants contributing to neutrophil resistance in this genetic background.   
NS88.2 genome sequence 
The NS88.2 genome draft consists of 298 contigs concatenated in a single circular chromosome of an 
estimated size of 1.7 Mbp with a G + C content of 39.35% and a multi-locus sequence type of 205. From 
Glimmer prediction, we found 1659 protein coding sequences (CDS) that account for 86.3% of the genome. 
The NS88.2 genome encodes many previously identified virulence factors, including streptolysin O (slo), 
Mac-1-like protein (mac), SmeZ, cysteine protease SpeB and C5a peptidase (scpA), though not 
streptococcal inhibitor of complement nor serum opacity factor. As an M-pattern D isolate (20), NS88.2 
also encodes the plasminogen-binding M protein-like protein, Prp, and two M-family proteins, Enn and 
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Mrp. Comparison of the genomic content of NS88.2 to 13 previously sequenced GAS genomes was 
undertaken via whole genome BLAST analysis (30) (Fig. 3). The majority of genetic diversity was confined 
to prophage-like content. NS88.2 contains at least one lysogenised prophage element, which encodes the 
streptococcal superantigen speL . Recombinational hotspots were also identified in the Mga regulon, 
wherein M family proteins are encoded, and the fibronectin- collagen- and T-antigen (FCT) locus (38). The 
FCT region is a streptococcal pathogenicity island, containing genes responsible for adherence to the host, 
including the GAS pilus components (39). Classification of NS88.2 by the FCT typing scheme corresponds 
to FCT-3, which also encodes a collagen-binding protein Cpa and fibronectin-binding protein PrtF2 (40). 
Identification of NS88.2 proteins that may interact with the host during infection was conducted via 
prediction of putatively surface-exposed proteins. A total of 190 genes encoding N-terminal secretion signal 
peptides and seven genes containing Gram-positive cell-wall anchor motifs were identified using hidden 
Markov models. 
Screening of the NS88.2 secretome 
GAS secrete many proteins which play immune-modulating roles during infection . Screening of the 
NS88.2, NS88.2rep and NS88.2covS supernatant protein fractions was conducted via two-dimensional 
electrophoresis to experimentally confirm the surface exposure of putatively secreted proteins (Fig. 4). To 
analyse peptide mass fingerprinting data, we used CDS data from the NS88.2 draft genome and formatted 
this information as a database which could be interrogated by the Mascot search engine (41). Multiple 
putatively cytoplasmic proteins were detected in the supernatant, as has been noted previously (42). 
Notably, of the 42 supernatant proteins identified (Table S1), SclA, which binds the alternative complement 
factor H and factor H-related protein 1 (43) and general stress protein 24 (Gls24) were both found in the 
supernatants of NS88.2 and NS88.2covS, but not in NS88.2rep. As with M1T1 GAS (15), expression of 
cysteine protease SpeB resulted in the degradation of much of the NS88.2rep secretome when grown in the 
absence of cysteine protease inhibitor E64 (data not shown). 
Expression of the NS88.2 transcriptome  
The covRS operon has been shown to control ~10-15% of the GAS genome, including many genes which 
have proven or putative roles in host-pathogen interactions (12). We subjected the parental NS88.2 strain 
bearing a mutated covS gene and the derivative NS88.2rep with intact covS to transcriptional microarray 
analysis during mid-logarithmic phase growth. Comparison of the transcriptional profile of NS88.2 to 
NS88.2rep showed significant de-repression of many virulence genes associated with resistance to innate 
immune responses, including emm, scpA, slo and the hyaluronic acid capsule biosynthesis genes hasA and 
hasB (Fig. 5). The sclA gene was also found to be highly up-regulated in NS88.2 compared with NS88.2rep. 
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A putative antibiotic resistance gene norA, and speB were found to be repressed in NS88.2 as a result of 
covS mutation, in accordance with previous studies (12, 17).  
To validate the microarray data, a panel of five genes was chosen for interrogation using quantitative real-
time PCR analysis (Fig. 6A). The strong up-regulation of the emm, sclA and hasA genes, and down-
regulation of speB in wild-type NS88.2 relative to the NS88.2rep strain were found to be consistent with the 
microarray analysis. In addition, expression of the gls24 gene was analysed and did not show significant 
differences in regulation between the two covS variants. However in vitro assays utilising purified Gls24 
protein suggest that expression of Gls24 may be regulated at the protein level via SpeB-mediated 
degradation (Fig. S1A). Exposure of GAS to whole blood is likely to play an important role in the 
regulation of GAS genes during infection, and gene expression levels were also investigated following 1 h 
incubation in sanguis (Fig. 6B). Transcripts were quantified relative to the proS housekeeping gene and the 
relative transcript abundance between NS88.2 and NS88.2rep; and both strains grown in THY and blood 
estimated. Growth of NS88.2 and NS88.2rep in blood resulted in a significant (P < 0.001) up-regulation of 
gls24 expression relative to growth of the same strains in THY. Other NS88.2 genes (sclA, emm) also 
displayed increased expression in response to exposure to blood, whilst speB showed consistent down-
regulation in response to growth in whole blood and covS mutation.         
SclA and Gls24 are necessary for NS88.2 survival in whole blood and neutrophil resistance 
Taken collectively, the presence of SclA and Gls24 in the NS88.2 secretome; up-regulation of sclA as a 
result of covS mutation; up-regulation of Gls24 after incubation in whole blood and the putative roles of 
these proteins in virulence indicated these factors may function alone or in synergy as virulence 
determinants of NS88.2. SclA exhibits a variety of binding propensities including alternative complement 
factor H (FH) and FH-related protein 1 (43), thrombin-activatable fibrinolysis inhibitor (44), low-density 
lipoproteins (45) and α2β1 integrins (35). It has also been shown that SclA is expressed during human 
infection, and that SclA elicits a humoral immune response against the collagen-like region of this protein 
(46). Gls24 contributes to the virulence of Enterococcus faecalis in an endocarditis model and is involved in 
stress tolerance of that pathogen (47, 48). To assess the effect of these proteins on NS88.2 innate immune 
resistance, the sclA and gls24 genes were isogenically deleted from the NS88.2 genome via precise allelic 
replacement with the cat gene. Complementation of the sclA and gls24 deficient strains was conducted via 
transformation with sclA or gls24 expressing pDCerm variants. 
The ability of NS88.2 and the sclA and gls24 isogenic deletion mutants to replicate in whole blood was 
assessed via Lancefield bactericidal assays (35) (Fig. 7A-B). Deletion of either sclA or gls24 significantly 
impaired the survival of the isogenic mutants in comparison to NS88.2 (NS88.2ΔsclA, P < 0.001; 
NS88.2Δgls24, P < 0.01). Complementation of the sclA or gls24 deletion via heterologous expression 
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restored survival in whole blood to both isogenic mutants (P > 0.05) (Fig. 7A-B). These changes were 
resultant of the activity of SclA and Gls24 in whole blood, as the growth kinetics of the isogenic mutants 
and complemented strains in THY were unchanged relative to the wild-type NS88.2 (Fig. S1B). Further 
examination of the role of SclA and Gls24 in innate immune responses was studied via measurement of the 
NS88.2 strains to neutrophil mediated killing (Fig. 7C-D). In comparison with the NS88.2 wild type, both 
NS88.2ΔsclA and NS88.2Δgls24 displayed significantly reduced neutrophil resistance (P < 0.05) whilst the 
complemented isogenic mutants exhibited neutrophil resistance equivalent to the wild-type (P > 0.05) (Fig. 
7C-D). This difference in resistance to neutrophil killing was independent of capsule expression as the 
isogenic deletion mutations and complemented strains express equivalent amounts of hyaluronic acid (Fig. 
S1C).   
DISCUSSION 
Recent increases in the incidences of life-threatening invasive GAS infections highlight the need to identify 
bacterial factors that explain epidemic behaviour. Despite extensive research focusing on Western 
centralised serotypes (8, 13), comparatively fewer studies have focused on disparate GAS strains originating 
from less developed areas. In many cases, rates of severe GAS diseases from these areas far exceed those 
observed in urban centres (49). The use of genomic sequencing and comparative bioinformatics has enabled 
high-throughput screening of other M2, M4, M6, M12 and M28 GAS strains, which determine 
distinguishing genetic features (50, 51). Currently, genomic research has focused exclusively on GAS 
serotypes which are more prevalent in developed countries such as M1, M3, M12 and M28 (52). Whilst 
these serotypes are frequently isolated from severe infections in the Western hemisphere, and/or are 
associated with distinct disease pathologies, the majority of GAS infections nonetheless occur in developing 
areas (53). Here, we have utilised genomic sequencing coupled with microarray and proteomic screening to 
identify a cohort of virulence factors which distinguish the hypervirulent, neutrophil resistant GAS isolate 
NS88.2.  
Genetic integrity of the two-component gene regulator covRS is a major determining factor of GAS 
virulence and colonisation. M1T1 GAS that bear the intact form of this operon are more highly suited to 
adherence and colonisation of host tissues (21). In this study we have characterised the emm 98.1 invasive 
isolate NS88.2. Phenotypically, this isolate is hypervirulent and neutrophil resistant (17), whilst the covS 
intact derivative (NS88.2rep) is avirulent, and exhibits increased biofilm formation and adhesion to 
epithelial cells. However, NS88.2 does not contain sda1 nor does it degrade neutrophil NETs, and so the 
mechanism of neutrophil resistance exhibited by NS88.2 is unaccounted for. Transcriptomic and proteomic 
data generated here demonstrates a cohort of immunomodulating virulence factors is up-regulated as a result 
of covS mutation in NS88.2, including the antiphagocytic M protein and SclA.  
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Isogenic deletion of sclA and gls24 from the NS88.2 genome was conducted to investigate their role in GAS 
pathogenesis, in resisting innate immune responses in particular. Multiple attempts to generate a double 
knockout mutant were unsuccessful. The finding that loss of sclA expression results in attenuated growth in 
whole blood and increased neutrophil sensitivity, is consistent with previous work describing the binding of 
complement regulatory factors to SclA (43, 44, 54). SclA is ubiquitously distributed in GAS strains; 
however sclA shows evidence of recombination and immune-selection analogous to the gene encoding M 
protein (46, 55), which gives credence to an anti-phagocytic role in pathogenesis. GAS binding of 
mammalian integrins with SclA may also facilitate escape from phagolysosomal killing via uptake into the 
cytoplasm (35). Previous work implicates Gls24 in the survival of E. faecalis during culture in human blood 
and in urine (56, 57). Gls24 was also found to be up-regulated at a protein level in response to growth of 
GAS in hyaluronic acid enriched media simulating an infection scenario (58) and during microarray 
analysis of murine soft tissue GAS infection (59). To date this is the first work demonstrating the direct 
impact of gls24 mutation on GAS survival and work is currently ongoing to determine the precise 
mechanism of action of Gls24 in systemic GAS infection.  
Mutations in covRS have been linked to the hypervirulence of GAS in animal models of infection (16, 17). 
Moreover, the recently published recovery of an emm 81.0 covS mutant GAS isolate following 13 days of 
human carriage, supports a model which predicts that such mutations occur clinically in a range of serotypes 
and in doing so escalate the severity of infection (17, 18, 60). Recent work has shown that functional emm 
and hasA genes, are also essential for the acquisition of covRS mutations (61). Data from this study supports 
a model in which GAS utilise a cohort of immune modulating virulence factors to attain a highly neutrophil 
resistant phenotype, leading to more severe infection.  
Despite ongoing research effort, the burden of GAS infection in developing areas and indigenous 
populations remains high, and is likely to be underestimated. Here, we demonstrate the utility of systems 
biology approaches to identify novel bacterial virulence factors. Such virulence factors may prove valuable 
targets for future therapeutic or vaccine interventions to treat this globally important pathogen.  
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FIGURE LEGENDS 
Fig. 1. Reduction of colonisation propensity due to covS inactivation in NS88.2. A Biofilm formation of 
covS inactive strains NS88.2 and NS88.2covS and covS intact strain NS88.2rep. B Adherence and invasion 
of HaCaT human keratinocytes by NS88.2, NS88.2rep and NS88.2covS. C Adherence of NS88.2, 
NS88.2rep and NS88.2covS to live mouse flanks. Panels B and C are expressed as a percentage of 
adherent/invasive bacteria of the original inoculum. Values shown for panels A and B are means ± standard 
deviations. *** indicates P < 0.001, ** indicates P < 0.01. 
Fig. 2. GAS mediated degradation of extracellular neutrophil DNA NETs. NET degradation by GAS 
strains NS88.2, NS88.2rep and NS88.2covS and M1T1 GAS strains 5448AP (animal passaged 5448 
encoding a truncated covS protein) and 5448Δsda1 (a 5448 derivative with sda1 isogenically deleted). 
Values shown are means ± standard deviations. *** indicates P < 0.001. 
Fig. 3. Genome-wide BLAST comparison of the NS88.2 draft genome to publicly available fully 
sequenced GAS genomes. Rings are annotated from outermost to innermost. Location of the variable 
fibronectin-binding, collagen-binding, T antigen (FCT) locus and MGA regulatory region (ring 1). Coloured 
blocks denoting BLAST matches of 80% - 100% nucleotide identity between NS88.2 and query genomes 
(rings 2 - 11; GenBank accession numbers are indicated in parentheses): NZ131 (NC_011375), MGAS6180 
(NC_007296), MGAS8232 (NC_003485), MGAS9469 (NC_008021) and MGAS2096 (NC_008023), 
MGAS10394 (NC_006086), Manfredo (NC_009332), MGAS10750 (NC_008024), SSI-1 (NC_004606) and 
MGAS315 (NC_004070), MGAS10270 (NC_008022), MGAS5005 (NC_007297) and SF370 
(NC_002737). Mapping coverage, red bars denote <200 fold coverage, blue bars denote >200 fold coverage 
(ring 12). Guanine and cytosine deviation (ring 13). Percent guanine and cytosine content (ring 14). NS88.2 
genome draft concatenated backbone in kilo base pairs (kbp, ring 15).   
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Fig. 4. Screening of the NS88.2 secretome. Secreted proteomic profiles of A NS88.2, B NS88.2rep and C 
NS88.2covS. Proteins identified via MALDI-TOF MS are indicated with numbered arrows (Table S1). 
Molecular masses of marker proteins (expressed as kilodaltons, kDa) and approximate isoelectric point (pI) 
values of each gel are indicated. Results shown are representative of duplicate gels from two independent 
protein isolations. 
Fig. 5. Differential regulation of genes between the parental NS88.2 wild-type strain, which contains a 
covS inactivating mutation and derivative NS88.2rep which encodes a functional covS gene. Selected 
genes are significantly differentially expressed (P < 0.05). 
Fig. 6. SclA and Gls24 are up-regulated in response to growth in whole blood. A Quantitative real-time 
PCR analysis of NS88.2 genes during mid-logarithmic phase growth. Fold-change in expression between 
NS88.2 relative to NS88.2rep is indicated. B Quantitative real-time PCR analysis of NS88.2 genes during 
mid-logarithmic phase growth in THY or after 1 h incubation in whole blood. Transcript abundance is 
expressed relative to the house-keeping gene proS. *** indicates P < 0.001. 
Fig. 7. Deletion of sclA or gls24 impairs NS88.2 growth in whole blood and resistance to neutrophil-
mediated killing. Fold growth of NS88.2, the sclA deficient mutant NS88.2ΔsclA and complemented 
derivative NS88.2ΔsclA (pDC-sclA) (A); the gls24 deficient mutant NS88.2Δgls24 and complemented 
derivative NS88.2Δgls24 (pDC-gls24) (B) after 3 h incubation in human whole blood. Ability of NS88.2, 
NS88.2ΔsclA, NS88.2ΔsclA (pDC-sclA) (C), NS88.2Δgls24 and NS88.2Δgls24 (pDC-gls24) (D) to survive 
neutrophil-mediated killing following co-culture with purified human PMNs. All assays were performed 
with a minimum of 3 donors and all assays were conducted in triplicate. Values shown for all panels are 



































Fig. S1 A Gls24 protein is degraded by GAS cysteine protease SpeB in vitro. Lane 1: SpeB and Casein; Lane 2: 
SpeB and Gls24; Lane 3: Casein; Lane 4: Gls24; Lane 5: SpeB. Molecular weight markers are given in kilo-
Daltons (kDa). B NS88.2, sclA and gls24 isogenic knock-mutant mutants and complemented strains exhibit 
comparable growth kinetics in Todd-Hewitt broth. C NS88.2, sclA and gls24 isogenic knock-out and 
complemented strains produce equivalent hyaluronic acid capsule. Capsule is expressed as femtograms of 
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1 Translation elongation factor G 4.83 76.5 9 22 
2 Transketolase 4.98 71.4 3 6 
3 Chaperone protein DnaK 4.62 64.9 8 19 
4 Cell division trigger factor 4.48 47.1 3 16 
5 Heat shock protein 60 family chaperone GroEL 4.75 42.1 8 32 
6 Collagen-like surface protein A 5.39 32.2 3 13 
7 Immunogenic secreted protein 5.42 54.1 4 10 
8 Group B streptococcal surface immunogenic protein 4.62 40.8 4 18 
9 Enolase 4.80 47.3 12 41 
10 Pyruvate kinase 4.96 54.5 10 24 
11 Xaa-His dipeptidase 4.87 51.3 6 19 
12 SSU ribosomal protein S1p 4.90 43.8 7 20 
13 Translation elongation factor Tu 4.89 43.9 9 36 
14 Non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase 5.06 50.4 6 19 
15 Arginine deiminase 4.99 46.3 6 18 
16 Phosphoglycerate kinase 4.82 42.1 11 42 
17 Translation elongation factor Ts 4.86 37.3 7 28 
18 glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 5.34 35.9 5 15 
19 L-lactate dehydrogenase 5.14 35.3 5 22 
20 Phosphate acetyltransferase 4.85 35.9 4 15 
21 6-phosphofructokinase 5.34 35.7 4 11 
22 Manganese-dependent inorganic pyrophosphatase 4.47 33.9 4 20 
23 Fructose-bisphosphate aldolase class II 4.98 31.2 5 32 
24 Protein serine/threonine phosphatase PrpC 4.60 27 5 31 
25 Adenylate kinase 4.74 23.7 4 29 
26 Translation elongation factor P 4.85 20.4 4 27 
27 Manganese superoxide dismutase 4.87 22.7 6 45 
28 Phosphoglycerate mutase 5.10 26 7 41 
29 Ribosomal subunit interface protein 4.45 21.1 4 34 
30 Peptidoglycan hydrolase, Autolysin2 4.66 25.5 4 31 
31 Alkyl hydroperoxide reductase protein C 4.65 20.5 3 22 
32 Sortase A, LPXTG specific 9.17 27.7 5 18 
33 Transcription elongation factor GreA 4.67 17.6 3 31 
34 General stress protein, Gls24 family 4.93 12.6 5 50 
35 Peptide deformylase 5.50 22.9 2 13 
36 Streptodornase B; Mitogenic factor 1 8.61 28.7 6 33 
37 Triosephosphate isomerase 4.57 26.6 6 33 
38 Ribosome recycling factor 5.58 20.6 4 22 
39 Streptokinase 5.58 50.2 9 28 
40 Secreted antigen GbpB/SagA/PcsB, putative peptidoglycan hydrolase 8.42 42 3 15 
41 Streptococcal pyrogenic exotoxin B (SpeB) 8.76 43.2 8 28 
42 M1_SPy_1686 (PepSY) 4.40 12.6 2 24 
a Isoelectric point calculated using Expasy compute pI/Mw tool 
b Number of tryptic peptides from mass spectrum matched to theoretical tryptic digest of protein sequence 
c Percentage coverage of protein sequence covered by Petide Matches 
Table S1. List of proteins identified in the supernatant of NS88.2, NS88.2rep and NS88.2covS. 
Supplemental unit 2 
